Order Article Reprints

Prat M, Salon M, Allain T, Dubreuil O, Noël G, Preisser L, Jean B, Cassard L, Lemée F, Tabah-Fish I, et al. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers. 2021; 13(8):1845. https://doi.org/10.3390/cancers13081845

Prat, Mélissa, Marie Salon, Thibault Allain, Olivier Dubreuil, Grégory Noël, Laurence Preisser, Bérangère Jean, Lydie Cassard, Fanny Lemée, Isabelle Tabah-Fish, and et al. 2021. "Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation" Cancers 13, no. 8: 1845. https://doi.org/10.3390/cancers13081845

Prat, M., Salon, M., Allain, T., Dubreuil, O., Noël, G., Preisser, L., Jean, B., Cassard, L., Lemée, F., Tabah-Fish, I., Pipy, B., Jeannin, P., Prost, J.-F., Barret, J.-M., & Coste, A. (2021). Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers, 13(8), 1845. https://doi.org/10.3390/cancers13081845